TherapeuticsMD, Inc.
TXMD · NASDAQ
12/31/2024 | 12/31/2023 | 12/31/2022 | 12/31/2021 | |
|---|---|---|---|---|
| Valuation | ||||
| PEG Ratio | 0.07 | 0.02 | -0.01 | 0.02 |
| FCF Yield | 11.80% | -204.92% | -8.78% | -101.14% |
| EV / EBITDA | -4.03 | -3.23 | 1.78 | -3.49 |
| Quality | ||||
| ROIC | -12.72% | -22.35% | 3,871.08% | -156.93% |
| Gross Margin | 100.00% | 29.19% | 98.00% | 78.33% |
| Cash Conversion Ratio | -0.32 | 6.25 | -3.80 | 1.86 |
| Growth | ||||
| Revenue 3-Year CAGR | -70.69% | -20.31% | 2.55% | -62.72% |
| Free Cash Flow Growth | 102.43% | -985.97% | 96.94% | 10.03% |
| Safety | ||||
| Net Debt / EBITDA | -0.71 | -0.44 | -2.47 | -1.67 |
| Interest Coverage | -501.05 | 0.00 | 0.00 | -4.25 |
| Efficiency | ||||
| Inventory Turnover | 0.00 | 0.00 | 0.00 | 2.47 |
| Cash Conversion Cycle | 553.28 | 855.56 | -564.87 | 234.19 |